Results 1 to 10 of about 308,174 (298)

HIV Drug Resistance

New England Journal of Medicine, 2004
To the Editor: Clavel and Hance (March 4 issue)1 review resistance to drugs used for the treatment of human immunodeficiency virus infection. Few data are available concerning patterns of antiretroviral-drug resistance among patients in developing countries.
Calmy, Alexandra, Pascual, Fernando, Ford, Nathan   +2 more
exaly   +7 more sources

Recommendations on data sharing in HIV drug resistance research. [PDF]

PLoS Medicine, 2023
• Human immunodeficiency virus (HIV) drug resistance has implications for antiretroviral treatment strategies and for containing the HIV pandemic because the development of HIV drug resistance leads to the requirement for antiretroviral drugs that may be
Seth C Inzaule, Mark J Siedner, Susan J Little, Santiago Avila-Rios, Alisen Ayitewala, Ronald J Bosch, Vincent Calvez, Francesca Ceccherini-Silberstein, Charlotte Charpentier, Diane Descamps, Susan H Eshleman, Joseph Fokam, Lisa M Frenkel, Ravindra K Gupta, John P A Ioannidis, Pontiano Kaleebu, Rami Kantor, Seble G Kassaye, Sergei L Kosakovsky Pond, Vinie Kouamou, Roger D Kouyos, Daniel R Kuritzkes, Richard Lessells, Anne-Genevieve Marcelin, Lawrence Mbuagbaw, Brian Minalga, Nicaise Ndembi, Richard A Neher, Roger Paredes, Deenan Pillay, Elliot G Raizes, Soo-Yon Rhee, Douglas D Richman, Kiat Ruxrungtham, Pardis C Sabeti, Jonathan M Schapiro, Sunee Sirivichayakul, Kim Steegen, Wataru Sugiura, Gert U van Zyl, Anne-Mieke Vandamme, Annemarie M J Wensing, Joel O Wertheim, Huldrych F Gunthard, Michael R Jordan, Robert W Shafer   +45 more
doaj   +2 more sources

HIV drug resistance and its associated factors among patients during interruption of antiretroviral therapy in China [PDF]

Frontiers in Microbiology
BackgroundThe prevalence of human immunodeficiency virus (HIV) drug resistance among people living with HIV (PLWH) who experience treatment interruptions is a significant concern.
Zhongbao Zuo, Wei Huang, Lei Liu, Miaomiao Li, Hongli Chen, Yi Feng, Lingjie Liao, Yiming Shao, Yuhua Ruan, Jing Wu, Hui Xing   +10 more
doaj   +2 more sources

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009) [PDF]

, 2013
Background:A major concern with using antiretroviral (ARV)-based products for HIV prevention is the potential spread of drug resistance, particularly from individuals who are HIV-infected but unaware of their status.
Barbara Mensch, Cliff Kelly, Gita Ramjee, John W. Mellors, Kailazarid Gomez, Krista Eskay, Lydia Soto-Torres, on behalf of the IPTc Taskforce, Pamina Gorbach, Photini Kiepiela, Shayhana Ganesh, Stephanie Horn, Urvi M. Parikh   +12 more
core   +34 more sources

HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016–2023) [PDF]

AIDS Research and Therapy
Background Large-scale HIV genotype drug resistance study has not been conducted in Chongqing. Methods A retrospective study was conducted on people living with HIV(PLWH) who received HIV-1 genotype resistance testing at Chongqing Public Health Medical ...
Wenwan Gao, Gang Zhou, Mei Li, Pengsen Wang, Jungang Li, Renni Deng   +5 more
doaj   +2 more sources

A Review: Understanding Molecular Mechanisms of Antibody-Dependent Enhancement in Viral Infections

Vaccines, 2023
Antibody Dependent Enhancement (ADE) of an infection has been of interest in the investigation of many viruses. It is associated with the severity of the infection.
Jyoti Sawant, Ajit Patil, Swarali Kurle
doaj   +1 more source

Exploring the Evolutionary History and Phylodynamics of Human Immunodeficiency Virus Type 1 Outbreak From Unnao, India Using Phylogenetic Approach

Frontiers in Microbiology, 2022
Certain rural and semiurban settings in the Unnao district, Uttar Pradesh, India observed an unprecedented increase in the detection of HIV cases during July 2017.
Ajit Patil, Sandip Patil, Amrita Rao, Sharda Gadhe, Swarali Kurle, Samiran Panda   +5 more
doaj   +1 more source

Drug resistant HIV [PDF]

BMJ, 2007
HIV has an impressive ability to replicate, mutate, and diversify, so developing drugs or vaccines that can fully contain the virus is a challenge. The only consistently successful way to prevent replication of HIV is to administer a potent combination regimen that contains at least two and preferably three antiretroviral drugs.
Hiroyu, Hatano, Steven G, Deeks
openaire   +2 more sources

Phylodynamic analysis reveals CRF01_AE dissemination between Japan and neighboring Asian countries and the role of intravenous drug use in transmission. [PDF]

PLoS ONE, 2014
BACKGROUND: One major circulating HIV-1 subtype in Southeast Asian countries is CRF01_AE, but little is known about its epidemiology in Japan. We conducted a molecular phylodynamic study of patients newly diagnosed with CRF01_AE from 2003 to 2010 ...
Teiichiro Shiino, Junko Hattori, Yoshiyuki Yokomaku, Yasumasa Iwatani, Wataru Sugiura, Japanese Drug Resistance HIV-1 Surveillance Network   +5 more
doaj   +1 more source

Adaptive HIV-1 evolutionary trajectories are constrained by protein stability [PDF]

, 2017
Despite the use of combination antiretroviral drugs for the treatment of HIV-1 infection, the emergence of drug resistance remains a problem. Resistance may be conferred either by a single mutation or a concerted set of mutations.
Kandathil, Shaun M., Lovell, Simon C., Olabode, Abayomi S., Robertson, David L.   +3 more
core   +5 more sources